Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Completed · Phase 2

Conditions studied: Prevention of Meningococcal Disease

In brief

The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years

Key facts

Study ID

NCT00262028

Run by

Novartis Vaccines

People needed

910

Starts

2005-04-01

Expected to finish

2006-11-01

Last updated by the study team

2016-02-11

Who can join

Age: 1 and older, up to 10. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Group 1: Healthy children 2-10 years of age;
• Group 2: Healthy toddlers 12-23 months of age; who are up to date with age appropriate immunizations for diphtheria, tetanus, pertussis, polio, hepatitis B, Hemophilus influenzae type b, and pneumococcus.

You may not qualify if…

• Group 1: Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease.
• Group 2: Subjects with a previous or suspected disease caused by N. meningitidis or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease.

Where it is running

• Kaiser Permanente Vaccine Study Center — Oakland, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.